Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Apogee Therapeutics, Inc.NASDAQ: APGE
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity rises 92.9% from a year ago
Total equity stood at $1.19B at the end of Q2 FY2026, up 92.9% from a year earlier and down 4.9% from the prior quarter. Over 3 fiscal years it compounded at +85.3% a year.
Context
- Total equity amounted to 89.4% of total assets at the end of Q2 FY2026, down 4.7 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +92.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 903.88M USD
- Year-over-year change
- +26.1%
- 3-year CAGR
- +85.3%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 903.88M | +26.1% |
| FY2024 | 2024-12-31 | 716.79M | +88.7% |
| FY2023 | 2023-12-31 | 379.91M | +167.4% |
| FY2022 | 2022-12-31 | 142.08M | — |
Total Equity vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +92.9% is the 3rd highest of 10, against a peer median of +25.9%.
- Total equity amounts to 89.4% of total assets for APGE, versus a peer median of 75.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.34B CNY | +387.0% | +48.4% | 33.7% |
| Sep 2026 | $1.27B USD | +25.9% | +10.4% | 75.7% | |
| Jun 2026 | $1.19B USD | +92.9% | +85.3% | 89.4% | |
| Sep 2026 | $1.15B USD | +104.9% | -6.9% | 95.5% | |
| Sep 2026 | $990.97M USD | +44.1% | +81.8% | 94.7% | |
| Jun 2026 | $607.04M USD | -23.3% | -11.9% | 56.5% | |
IRONDisc Medicine, Inc. | Sep 2026 | $604.25M USD | +5.4% | +61.2% | 86.4% |
| Mar 2026 | $487.35M USD | +26.2% | +16.2% | 75.9% | |
| Jun 2026 | -$12.78M USD | -128.8% | -9.1% | 1.5% | |
| Mar 2026 | -$229M USD | -251.4% | — | 17.7% | |
| Peer median (excluding APGE) | — | +25.9% | +13.3% | 75.7% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.